Taken together, our results indicate that the MAZ/MAP2K2/ERK pathway plays a key role in the proliferation mechanism of ccRCC and provides a potential therapeutic target for ccRCC treatment. This evidence concerns the gene MAP2K2 and nonpapillary renal cell carcinoma.